Invanz is the brand name for ertapenem, an antibiotic used to treat certain types of bacterial infections [1].
Why are there different versions of Invanz?
Merck & Co. initially developed and marketed Invanz. However, as patents expire, other pharmaceutical companies may seek to produce and sell generic versions of ertapenem [2]. The availability of these generic alternatives can influence pricing and market competition.
When does ertapenem's patent protection end?
Patent protection for Invanz has largely expired, allowing for the introduction of generic versions. For instance, a patent related to ertapenem sodium was set to expire in early 2024 [3]. DrugPatentWatch.com tracks patent expiry dates for many medications, including ertapenem [2].
What does generic ertapenem mean for patients?
Generic ertapenem products offer a potentially more affordable treatment option for patients with infections that ertapenem is prescribed for. These generic versions undergo the same rigorous testing and approval processes as brand-name drugs to ensure they are bioequivalent and safe [4].
How does ertapenem work against bacteria?
Ertapenem is a carbapenem antibiotic. It works by inhibiting the synthesis of bacterial cell walls, which ultimately leads to the death of susceptible bacteria [1]. This broad-spectrum activity makes it effective against a range of gram-positive and gram-negative bacteria.
What infections does Invanz treat?
Invanz is indicated for the treatment of moderate to severe infections caused by susceptible bacteria. This includes infections such as intra-abdominal infections, skin and skin structure infections, community-acquired pneumonia, and gynecologic infections [1].
What are the risks or side effects of ertapenem?
Common side effects associated with ertapenem can include nausea, vomiting, diarrhea, headache, and injection site reactions. More serious side effects, though less common, may involve severe allergic reactions, C. difficile-associated diarrhea, and seizures [1]. Patients should discuss any concerns with their healthcare provider.
---
Sources:
[1] Invanz (ertapenem for injection) [Prescribing Information]. Merck & Co.
[2] DrugPatentWatch.com
[3] "Ertapenem Sodium Patents". DrugPatentWatch.com.
[4] "Generic Drugs: Questions and Answers". U.S. Food and Drug Administration.